Lilly (LLY.US) explores new uses for "fat loss drug" Zepbound to target high-risk populations such as diabetes
AInvestWednesday, Oct 2, 2024 4:10 am ET
1min read
DAVE --
GLP --
LLY --
NVO --

Eli Lilly and Co. (LLY.US) is exploring new uses for its weight loss drug Zepbound to lower the incidence of diabetes and other high-risk conditions in people who are not overweight, even as the company's CEO Dave Ricks revealed plans to test the drug as a maintenance therapy for people with a body mass index (BMI) below the overweight level. Zepbound and the company's other weight loss candidate, orforglipron, are currently targeted at patients with a BMI of 30 or higher, as well as those with a BMI of 27 or higher who have other weight-related health issues.

Ricks said the company hopes to lower the BMI threshold to 25 or lower to study the drug as a potential means of preventing diabetes, stroke or vascular dementia. The strategy is especially meaningful for certain groups of people with lower BMIs but higher diabetes risk, such as Pacific Islanders.

However, Eli Lilly still believes that using Zepbound for aesthetic weight loss is inappropriate.

Zepbound, also known as tirzepatide, is a GLP-1 drug that competes with Novo Nordisk's semaglutide, which is sold under the brand names Ozempic and Wegovy.

GLP-1 drugs have been in the spotlight for their potential in weight loss and glucose control. In addition, several companies are actively developing weight loss drugs, including Amgen (AMGN.US), Pfizer (PFE.US), AstraZeneca (AZN.US), Roche (RHHBY.US), Boehringer Ingelheim, Viking Therapeutics (VKTX.US), Altimmune (ALT.US), Zealand Pharma and Sutro Biopharma (GPCR.US), all of which are seeking to develop new solutions for obesity and related diseases.

Disclaimer: the above is a summary showing certain market information. AInvest is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from a third party source. Communications displaying market prices, data and other information available in this post are meant for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.